| Tayler Marie Rydalch, PMHNP, BC | |
|
2601 Evans Ave, Butte, MT 59701-3833 | |
| (406) 498-8198 | |
| Not Available |
| Full Name | Tayler Marie Rydalch |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Psychiatric/mental Health |
| Location | 2601 Evans Ave, Butte, Montana |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235862467 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LP0808X | Nurse Practitioner - Psychiatric/mental Health | APRN-195648 (Montana) | Primary |
| Entity Name | Tayler Rydalch Pmhnp-bc Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114649639 PECOS PAC ID: 8921475377 Enrollment ID: O20221027003043 |
News Archive
Researchers have discovered that deleting a specific gene in mice prevents them from becoming obese even on a high fat diet, a finding they believe may be replicated in humans.
Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces that the US Food and Drug Administration has accepted its Investigational New Drug application to initiate a Phase 3 pivotal study of ST10, its novel oral iron-replacement therapy, for the treatment of iron deficiency anaemia in pre-dialysis patients with chronic kidney disease. The Company plans to initiate the Phase 3 study in the US in H1 2014 and positive data would be the cornerstone of a subsequent NDA submission.
Ohio Governor John Kasich on Wednesday signed a law that would prohibit abortion coverage from the state insurance exchange Ohio must create under the federal health care law. ... The law bans Ohio citizens from being able to purchase insurance through the exchange that includes abortion coverage, even if they pay for it with their own money, said Kellie Copeland, executive director of NARAL Pro-Choice Ohio, who criticized the bill.
Patient studies of a new sensing device have proved it can provide early warning of the potential failure of breast reconstruction surgery, making it easier to take effective remedial action.
R-Tech Ueno, is pleased to announce that the Phase 2a clinical study of RK-023 to treat androgenetic alopecia was completed by January 21, 2011.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Tayler Marie Rydalch, PMHNP, BC 2601 Evans Ave, Butte, MT 59701-3833 Ph: (406) 498-8198 | Tayler Marie Rydalch, PMHNP, BC 2601 Evans Ave, Butte, MT 59701-3833 Ph: (406) 498-8198 |
News Archive
Researchers have discovered that deleting a specific gene in mice prevents them from becoming obese even on a high fat diet, a finding they believe may be replicated in humans.
Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces that the US Food and Drug Administration has accepted its Investigational New Drug application to initiate a Phase 3 pivotal study of ST10, its novel oral iron-replacement therapy, for the treatment of iron deficiency anaemia in pre-dialysis patients with chronic kidney disease. The Company plans to initiate the Phase 3 study in the US in H1 2014 and positive data would be the cornerstone of a subsequent NDA submission.
Ohio Governor John Kasich on Wednesday signed a law that would prohibit abortion coverage from the state insurance exchange Ohio must create under the federal health care law. ... The law bans Ohio citizens from being able to purchase insurance through the exchange that includes abortion coverage, even if they pay for it with their own money, said Kellie Copeland, executive director of NARAL Pro-Choice Ohio, who criticized the bill.
Patient studies of a new sensing device have proved it can provide early warning of the potential failure of breast reconstruction surgery, making it easier to take effective remedial action.
R-Tech Ueno, is pleased to announce that the Phase 2a clinical study of RK-023 to treat androgenetic alopecia was completed by January 21, 2011.
› Verified 9 days ago
Carla Campbell, NP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 55 E Galena St, Butte, MT 59701 Phone: 406-723-4075 Fax: 406-723-5060 | |
Elizabeth Ann Church, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1255 W Side Blvd, Butte, MT 59701 Phone: 406-490-9664 | |
Mrs. Eleanor Stacey Combs, PMHNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 101 Ponderosa Dr, Butte, MT 59701 Phone: 406-723-7176 | |
Dr. Rebecca Romine, DNP, APRN, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 55 E Galena St, Butte, MT 59701 Phone: 406-782-0461 | |
Mr. Harold James Horine Iii, DNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 445 Centennial Ave, Butte, MT 59701 Phone: 406-723-4075 | |
Hannah Kasperick, FNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 435 S Crystal St Ste 300, Butte, MT 59701 Phone: 406-496-3600 | |
Peggy Jane Wolstein, PMHNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 55 Basin Creek Rd, Butte, MT 59701 Phone: 406-491-2174 |